Anti-ANPRA/ NPR1/ ANPa monoclonal antibody
Anti-ANPRA/ NPR1/ ANPa antibody for FACS & in-vivo assay
Go to NPR1/NPR1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-T71230-Ab-1/ GM-Tg-hg-T71230-Ab-2 | Anti-Human NPR1 monoclonal antibody | Human |
GM-Tg-rg-T71230-Ab-1/ GM-Tg-rg-T71230-Ab-2 | Anti-Rat NPR1 monoclonal antibody | Rat |
GM-Tg-mg-T71230-Ab-1/ GM-Tg-mg-T71230-Ab-2 | Anti-Mouse NPR1 monoclonal antibody | Mouse |
GM-Tg-cynog-T71230-Ab-1/ GM-Tg-cynog-T71230-Ab-2 | Anti-Cynomolgus/ Rhesus macaque NPR1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-T71230-Ab-1/ GM-Tg-felg-T71230-Ab-2 | Anti-Feline NPR1 monoclonal antibody | Feline |
GM-Tg-cang-T71230-Ab-1/ GM-Tg-cang-T71230-Ab-2 | Anti-Canine NPR1 monoclonal antibody | Canine |
GM-Tg-bovg-T71230-Ab-1/ GM-Tg-bovg-T71230-Ab-2 | Anti-Bovine NPR1 monoclonal antibody | Bovine |
GM-Tg-equg-T71230-Ab-1/ GM-Tg-equg-T71230-Ab-2 | Anti-Equine NPR1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-T71230-Ab-1/ GM-Tg-hg-T71230-Ab-2; GM-Tg-rg-T71230-Ab-1/ GM-Tg-rg-T71230-Ab-2; GM-Tg-mg-T71230-Ab-1/ GM-Tg-mg-T71230-Ab-2; GM-Tg-cynog-T71230-Ab-1/ GM-Tg-cynog-T71230-Ab-2; GM-Tg-felg-T71230-Ab-1/ GM-Tg-felg-T71230-Ab-2; GM-Tg-cang-T71230-Ab-1/ GM-Tg-cang-T71230-Ab-2; GM-Tg-bovg-T71230-Ab-1/ GM-Tg-bovg-T71230-Ab-2; GM-Tg-equg-T71230-Ab-1/ GM-Tg-equg-T71230-Ab-2 |
Products Name | Anti-NPR1 monoclonal antibody |
Format | mab |
Target Name | NPR1 |
Protein Sub-location | Transmembrane Protein |
Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-NPR1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | Products Developing | Multi-species ANPRA/ NPR1/ ANPa VLP (virus-like particle) (Products Developing) |
Target information
Target ID | GM-T71230 |
Target Name | NPR1 |
Gene ID | 4881,18160,24603,715598,490455,101080682,533048,100061959 |
Gene Symbol and Synonyms | ANPa,ANPRA,GC-A,Gca,GUC2A,GUCY2A,NPR-A,NPR1,NPRA,Pndr |
Uniprot Accession | P16066,P18910 |
Uniprot Entry Name | ANPRA_HUMAN,ANPRA_RAT |
Protein Sub-location | Transmembrane Protein |
Category | Therapeutics Target |
Disease | N/A |
Gene Ensembl | ENSG00000169418 |
Target Classification | Pathway |
The target: NPR1, gene name: NPR1, also named as ANPRA, ANPa, GUC2A, GUCY2A, NPRA. Guanylyl cyclases, catalyzing the production of cGMP from GTP, are classified as soluble and membrane forms (Garbers and Lowe, 1994 [PubMed 7982997]). The membrane guanylyl cyclases, often termed guanylyl cyclases A through F, form a family of cell-surface receptors with a similar topographic structure: an extracellular ligand-binding domain, a single membrane-spanning domain, and an intracellular region that contains a protein kinase-like domain and a cyclase catalytic domain. GC-A and GC-B function as receptors for natriuretic peptides; they are also referred to as atrial natriuretic peptide receptor A (NPR1) and type B (NPR2; MIM 108961). Also see NPR3 (MIM 108962), which encodes a protein with only the ligand-binding transmembrane and 37-amino acid cytoplasmic domains. NPR1 is a membrane-bound guanylate cyclase that serves as the receptor for both atrial and brain natriuretic peptides (ANP (MIM 108780) and BNP (MIM 600295), respectively).[supplied by OMIM, May 2009].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.